Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.
Salivary Gland Tumors|Head and Neck Cancer
DRUG: Nedaplatin|DRUG: Docetaxel|RADIATION: Intensity-modulated radiotherapy
Disease-free survival, from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 2 years, 2 years
Overall survival rate, from date of enrollment until date of first death from any cause, assessed up to 2 years, 2 years|Acute toxicity profiles, graded according to the NCI CTCAE version 3.0, Number of participants with treatment-related acute toxicity as assessed weekly by CTCAE v3.0 during the course of treatment, up to 6 weeks|Late toxicity profiles, graded according to the NCI CTCAE version 3.0, Number of participants with treatment-related late toxicity as assessed every 3 months by CTCAE v3.0 up to 2 years, up to 2 years|Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment, QoL score will be documented on each weekend during the course of radiotherapy, participants will be followed for the duration of hospital stay, an expected average of 6 weeks
This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.